Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey


Autoři: Enrico Maria Trecarichi aff001;  Gabriele Giuliano aff002;  Chiara Cattaneo aff003;  Stelvio Ballanti aff004;  Marianna Criscuolo aff005;  Anna Candoni aff006;  Francesco Marchesi aff007;  Marica Laurino aff008;  Michelina Dargenio aff009;  Rosa Fanci aff010;  Mariagiovanna Cefalo aff011;  Mario Delia aff012;  Angelica Spolzino aff013;  Laura Maracci aff014;  Gianpaolo Nadali aff015;  Alessandro Busca aff016;  Maria Ilaria Del Principe aff017;  Rosa Daffini aff003;  Edoardo Simonetti aff004;  Giulia Dragonetti aff005;  Maria Elena Zannier aff006;  Livio Pagano aff005;  Mario Tumbarello aff002
Působiště autorů: Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, “Magna Graecia” University, Catanzaro, Italy aff001;  Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy aff002;  Hematology, ASST-Spedali Civili, Brescia, Italy aff003;  Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia, Perugia, Italy aff004;  Dipartimento scienze radiologiche radioterapiche ed ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy aff005;  Clinica Ematologica, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata, Udine, Italy aff006;  Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy aff007;  Department of Medicine, Haematology Unit, University of Padova, Italy aff008;  Unità di Ematologia e Trapianto di cellule staminali, Azienda Ospedaliera Vito Fazzi, Lecce, Italy aff009;  SOD complessa di Ematologia, Azienda Ospedaliero-Universitaria Careggi e Università di Firenze, Florence, Italy aff010;  Hematology, San Eugenio Hospital, Rome, Italy aff011;  Hematology Section, Department of Emergency and Organ Transplant, University of Bari, Bari, Italy aff012;  Department of Medicine and Surgery, University of Parma, Parma, Italy; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy aff013;  Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy aff014;  U.O.C. Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale Borgo Roma, Verona, Italy aff015;  Department of Hematology and Stem Cell Transplant Unit, AOU Citta' della Salute e della Scienza, Torino, Italy aff016;  Dipartimento di Biomedicina e Prevenzione; Università degli studi di Roma "Tor Vergata", Roma, Italy aff017;  Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy aff018;  Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy aff019
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224465

Souhrn

Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one of the most frequent cause of such infections. In this study, we aimed to describe risk factors for resistance to third generation cephalosporins and prognostic factors, including the impact of third generation cephalosporins resistance, in patients with HM and BSIs caused by E. coli. Three hundred forty-two cases of E. coli BSIs were collected during the study period (from January 2016 to December 2017). The percentage of resistance to third generation cephalosporins was 25.7%. In multivariate analysis, the variables recent endoscopic procedures, culture-positive surveillance rectal swabs for multidrug-resistant bacteria, antibiotic prophylaxis with fluoroquinolones, and prolonged neutropenia were independently associated with bloodstream infections caused by a third generation cephalosporins resistant E. coli. The overall 30-day mortality rate was 7.1%. Cox regression revealed that significant predictors of mortality were acute hepatic failure, septic shock, male sex, refractory/relapsed HM, and third generation cephalosporins resistance by E. coli isolate. In conclusion, resistance to third generation cephalosporins adversely affected the outcomes of bloodstream infections caused by E. coli in our cohort of HM patients. We also found a significant correlation between prophylaxis with fluoroquinolones and resistance to third generation cephalosporins by E. coli isolates.

Klíčová slova:

Antibiotic resistance – Antibiotics – Antimicrobial resistance – Bloodstream infections – Cancer risk factors – Death rates – Escherichia coli – Hematology


Zdroje

1. Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer. Curr Opin Infect Dis. 2014;27: 200–210. doi: 10.1097/QCO.0000000000000038 24573013

2. Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21: 337–343. doi: 10.1016/j.cmi.2014.11.022 25595706

3. Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91: 1076–1081. doi: 10.1002/ajh.24489 27428072

4. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: Clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333–341. doi: 10.1093/jac/dkp411 19959544

5. Scheich S, Weber S, Reinheimer C, Wichelhaus TA, Hogardt M, Kempf VAJ, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. 2018;97: 2225–2234. doi: 10.1007/s00277-018-3423-5 29974230

6. Montassier E, Batard E, Gastinne T, Potel G, De La Cochetière MF. Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32: 841–850. doi: 10.1007/s10096-013-1819-7 23354675

7. Ma J, Li N, Liu Y, Wang C, Liu X, Chen S, et al. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial e coli bacteremia in adult patients with hematological disease. Med (United States). 2017;96: e6959.

8. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58: 299–307. doi: 10.1016/j.jinf.2009.02.002 19272650

9. Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42: 403–409. doi: 10.1016/j.ijantimicag.2013.07.018 24071027

10. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. N Engl J Med. 2005;353: 977–987. doi: 10.1056/NEJMoa044097 16148283

11. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97: 1717–1726. doi: 10.1007/s00277-018-3341-6 29705860

12. European Centre for Disease Prevention and Contro. Annual epidemiological report on communicable diseases in Europe 2008. Report on the state of communicable diseases in the EU and EEA/EFTA countries. Available at: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf%0D.

13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39: 165–228. doi: 10.1007/s00134-012-2769-8 23361625

14. European Centre for Disease Prevention and Contro. Surveillance of antimicrobial resistance in Europe (2017). Available at: https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016.

15. Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for Study of Infectious Diseases. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91: 115–121. doi: 10.1007/s00277-011-1247-7 21556875

16. Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: Factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92: 533–541. doi: 10.1007/s00277-012-1631-y 23161391

17. Ben-Chetrit E, Eldaim MA, Bar-Meir M, Dodin M, Katz DE. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia. Int J Antimicrob Agents. 2019;53: 423–428. doi: 10.1016/j.ijantimicag.2018.12.003 30572008

18. Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum -lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol. 2012;7: 1173–1189. doi: 10.2217/fmb.12.100 23030423

19. Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20: 1357–1362. doi: 10.1111/1469-0691.12747 24980276

20. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: Results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21: 1106.e1–1106.e8.

21. Mikulska M, Cordonnier C. Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays? Clin Microbiol Infect. 2018;24: 678–679. doi: 10.1016/j.cmi.2018.02.031 29549060

22. Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, et al. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017;65: 1819–1828. doi: 10.1093/cid/cix646 29020364

23. Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76: 20–37. doi: 10.1016/j.jinf.2017.10.009 29079323

24. Lye DC, Earnest A, Ling ML, Lee TE, Yong HC, Fisher DA, et al.The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2018;18:502–508.

25. Tang Y, Cheng Q, Yang Q, Liu J, Zhang D, Cao Wet al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection. 2018;46:513–521. doi: 10.1007/s15010-018-1151-3 29767394

26. Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2009;64: 320–326. doi: 10.1016/j.diagmicrobio.2009.02.008 19345033

27. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance. JAMA—J Am Med Assoc. 2018;320: 984–994.

28. Gudiol C, Royo-cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, et al. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. 2017;61: 1–8.


Článek vyšel v časopise

PLOS One


2019 Číslo 10